218 related articles for article (PubMed ID: 17711901)
1. Congenital heart block: clinical features and therapeutic approaches.
Gordon PA
Lupus; 2007; 16(8):642-6. PubMed ID: 17711901
[TBL] [Abstract][Full Text] [Related]
2. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study.
Friedman DM; Kim MY; Copel JA; Davis C; Phoon CK; Glickstein JS; Buyon JP;
Circulation; 2008 Jan; 117(4):485-93. PubMed ID: 18195175
[TBL] [Abstract][Full Text] [Related]
3. Prevention of complete heart block in children of mothers with anti-SSA/Ro and anti-SSB/La autoantibodies: detection and treatment of first-degree atrioventricular block.
Mevorach D; Elchalal U; Rein AJ
Curr Opin Rheumatol; 2009 Sep; 21(5):478-82. PubMed ID: 19584727
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment with fluorinated glucocorticoids to the natural history of autoantibody-associated congenital heart block: retrospective review of the research registry for neonatal lupus.
Saleeb S; Copel J; Friedman D; Buyon JP
Arthritis Rheum; 1999 Nov; 42(11):2335-45. PubMed ID: 10555029
[TBL] [Abstract][Full Text] [Related]
5. Perinatal outcome of fetus with isolated congenital second degree atrioventricular block without maternal anti-SSA/Ro-SSB/La antibodies.
Chang YL; Hsieh PC; Chang SD; Chao AS; Liang CC; Soong YK
Eur J Obstet Gynecol Reprod Biol; 2005 Oct; 122(2):167-71. PubMed ID: 16219517
[TBL] [Abstract][Full Text] [Related]
6. Controversies in the therapy of isolated congenital complete heart block.
Dolara A; Favilli S
J Cardiovasc Med (Hagerstown); 2010 Jun; 11(6):426-30. PubMed ID: 20421761
[TBL] [Abstract][Full Text] [Related]
7. Congenital complete heart block and maternal connective tissue disease.
Jayaprasad N; Johnson F; Venugopal K
Int J Cardiol; 2006 Sep; 112(2):153-8. PubMed ID: 16815568
[TBL] [Abstract][Full Text] [Related]
8. Neurological outcome in isolated congenital heart block and hydrops fetalis.
Breur JM; Gooskens RH; Kapusta L; Stoutenbeek P; Visser GH; van den Berg P; Meijboom EJ
Fetal Diagn Ther; 2007; 22(6):457-61. PubMed ID: 17652937
[TBL] [Abstract][Full Text] [Related]
9. Prolonged QT interval and 2:1 atrioventricular block.
Battiste CE
Kans Med; 1993 Jan; 94(1):16-9. PubMed ID: 8433542
[No Abstract] [Full Text] [Related]
10. Arrhythmias presenting in neonatal lupus.
Brucato A; Previtali E; Ramoni V; Ghidoni S
Scand J Immunol; 2010 Sep; 72(3):198-204. PubMed ID: 20696016
[TBL] [Abstract][Full Text] [Related]
11. Prevention of congenital heart block in children of SSA-positive mothers.
Brucato A
Rheumatology (Oxford); 2008 Jun; 47 Suppl 3():iii35-7. PubMed ID: 18504284
[TBL] [Abstract][Full Text] [Related]
12. Concomitant disappearance of electrocardiographic abnormalities and of acquired maternal autoantibodies during the first year of life in infants who had QT interval prolongation and anti-SSA/Ro positivity without congenital heart block at birth.
Cimaz R; Meroni PL; Brucato A; Fesstovà V; Panzeri P; Goulene K; Stramba-Badiale M
Arthritis Rheum; 2003 Jan; 48(1):266-8. PubMed ID: 12528128
[No Abstract] [Full Text] [Related]
13. Electrocardiographic abnormalities in infants born from mothers with autoimmune diseases--a multicentre prospective study.
Gerosa M; Cimaz R; Stramba-Badiale M; Goulene K; Meregalli E; Trespidi L; Acaia B; Cattaneo R; Tincani A; Motta M; Doria A; Zulian F; Milanesi O; Brucato A; Riboldi P; Meroni PL
Rheumatology (Oxford); 2007 Aug; 46(8):1285-9. PubMed ID: 17449486
[TBL] [Abstract][Full Text] [Related]
14. Outcome of infants from mothers with anti-SSA/Ro antibodies.
Motta M; Rodriguez-Perez C; Tincani A; Lojacono A; Chirico G
J Perinatol; 2007 May; 27(5):278-83. PubMed ID: 17363909
[TBL] [Abstract][Full Text] [Related]
15. A combination therapy to treat second-degree anti-Ro/La-related congenital heart block: a strategy to avoid stable third-degree heart block?
Ruffatti A; Milanesi O; Chiandetti L; Cerutti A; Gervasi MT; De Silvestro G; Pengo V; Punzi L
Lupus; 2012 May; 21(6):666-71. PubMed ID: 22187163
[TBL] [Abstract][Full Text] [Related]
16. Outcome of high-risk neonates with congenital complete heart block paced in the first 24 hours after birth.
Glatz AC; Gaynor JW; Rhodes LA; Rychik J; Tanel RE; Vetter VL; Kaltman JR; Nicolson SC; Montenegro L; Shah MJ
J Thorac Cardiovasc Surg; 2008 Sep; 136(3):767-73. PubMed ID: 18805283
[TBL] [Abstract][Full Text] [Related]
17. Specificity and effector mechanisms of autoantibodies in congenital heart block.
Wahren-Herlenius M; Sonesson SE
Curr Opin Immunol; 2006 Dec; 18(6):690-6. PubMed ID: 17011766
[TBL] [Abstract][Full Text] [Related]
18. Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies.
Skog A; Wahren-Herlenius M; Sundström B; Bremme K; Sonesson SE
Pediatrics; 2008 Apr; 121(4):e803-9. PubMed ID: 18381509
[TBL] [Abstract][Full Text] [Related]
19. Isolated congenital atrioventricular block diagnosed in utero: natural history and outcome.
Breur JM; Kapusta L; Stoutenbeek P; Visser GH; van den Berg P; Meijboom EJ
J Matern Fetal Neonatal Med; 2008 Jul; 21(7):469-76. PubMed ID: 18570127
[TBL] [Abstract][Full Text] [Related]
20. Indications for pacing in patients with congenital heart disease.
Villain E
Pacing Clin Electrophysiol; 2008 Feb; 31 Suppl 1():S17-20. PubMed ID: 18226027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
